Currently in:
Lung Cancer Treatment
More Searches ...

Lung Cancer Causes
Lung Cancer Stages
Lung Cancer Symptoms
Lung Cancer Treatment
Lung Cancer
Lung Tumor
Lung Disease

OSI Pharmaceuticals Announces Acceptance Of Tarceva Supplemental New Drug Application For Review By The U.S. Food And Drug Administration

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental New Drug Application (sNDA) for the use of Tarceva® (erlotinib) as a first-line maintenance treatment for patients with advanced non-small cell lung (continued...)

Nicotine's Double Role In Lung Cancer

A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers. The results of the early phase animal model study were reported in the June 15 issue of the American Journal of Respiratory and Critical Care Medicine. Changes in (continued...)

Defeating nicotine's double role in lung cancer

(American Thoracic Society) A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers. (continued...)

Maintenance Treatment With Avastin And Tarceva Aids Lung Cancer

BASEL -- Roche announced today that the Phase III ATLAS study showed patients with advanced non-small cell lung cancer (NSCLC) who received Avastin(R) (bevacizumab) and Tarceva(R) (erlotinib) as combined first-line maintenance treatment had a 39 percent improvement in the time they lived without the (continued...)

New Treatment Approach Gives Patients With Incurable Lung Cancer More Time Without Disease Progression Compared To Placebo

Results from a Phase III study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida today show that patients with advanced non-small cell lung cancer (NSCLC) who received erlotinib (Tarceva®) as first-line maintenance treatment benefited from a significant (continued...)

Bayer And Onyx Initiate Phase III Trial Of Nexavar(R) In Non-small Cell Lung Cancer

Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous (continued...)

Prophylactic cranial irradiation prevents early lung cancer metastases to the brain

A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases (continued...)

Alimta(R) (pemetrexed For Injection) Receives Positive Opinion From CHMP As Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer

Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA® (pemetrexed for injection) as monotherapy for the maintenance treatment of locally advanced or metastatic (continued...)

Brain irradiation in lung cancer

(Medical College of Wisconsin) A national Radiation Therapy Oncology Group study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer (continued...)

Lung tumor promotion by curcumin

lung-tumors.info - Lung cancer tumors

Latest news and articles about Lung cancer. Up-to-date information about the Symptoms of Lung Cancer, lung tumors, causes and possible treatments. In order to read the article, please click on more... below the article. For more topics click on the left hand menu

Lung Cancer Treatment

Lung tumor promotion by curcumin

Curcumin exhibits anti-inflammatory and antitumor activity and is being tested in clinical trials as a chemopreventive agent for colon cancer. Curcumin's chemopreventive activity was tested in a transgenic mouse model of lung cancer that expresses the human Ki-ras^G12C allele in a doxycycline (DOX) inducible and lung-specific manner. The effects of curcumin were compared with the lung tumor promoter, butylated hydroxytoluene (BHT), and the lung cancer chemopreventive agent, sulindac. Treatment of DOX-induced mice with dietary curcumin increased tumor multiplicity (36.3 ± 0.9 versus 24.3 ± 0.2) and progression to later stage lesions, results which were similar to animals that were co-treated with DOX/BHT. Microscopic examination showed that the percentage of lung lesions that were adenomas and adenocarcinomas increased to 66% in DOX/BHT, 66% in DOX/curcumin and 49% in
Continue at news source...)

News Rss
Articles Rss